AMD linked to increased incidence of death from stroke, cardiovascular events

Article

Age-related macular degeneration (AMD) may be a useful indicator for predicting death from stroke or cardiovascular disease, according to a study published online ahead of print by the British Journal of Ophthalmology.

Age-related macular degeneration (AMD) may be a useful indicator for predicting death from stroke or cardiovascular disease, according to a study published online ahead of print by the British Journal of Ophthalmology.

Jennifer S. Tan at the University of Sydney, Australia and team assessed 3654 subjects (age ≥49 years), with follow-up at five (n=2335) and 10 (n=1952) years. Assessment included physical risk factors and medical history; causes of death were confirmed by the Australian National Death Index.

Early presentation of AMD was, after adjusting for traditional cardiovascular risk factors, linked to a twofold increase in cardiovascular mortality over a 10-year period in subjects aged <75 years at baseline. Late presentation of AMD was, after adjusting for age and gender, associated with a five times increased incidence of cardiovascular mortality and a 10 times increased incidence of stroke mortality, again in subjects aged <75 years at baseline.

The researchers concluded that this association of AMD with mortality from stroke and cardiovascular events may have implications for intravitreal anti-VEGF therapies, which are also linked with an increased risk of stroke.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.